Prostate Cell News Volume 4.01 | Jan 11 2013

LABORATORY RESEARCH

Dp44mT Targets the AKT, TGF-β and ERK Pathways via the Metastasis Suppressor NDRG1 in Normal Prostate Epithelial Cells and Prostate Cancer Cells
Scientists determined how the tumorigenic phosphoinositide 3-kinase/protein kinase B (PI3K/AKT), tumor-suppressive phosphatase and tensin homologue deleted on chromosome 10 and transforming growth factor-β (TGF-β) pathways are integrated via the metastasis suppressor, N-myc downstream-regulated gene-1 (NDRG1). [Br J Cancer] Full Article

Novel Interaction Between the Co-Chaperone Cdc37 and Rho GTPase Exchange Factor Vav3 Promotes Androgen Receptor Activity and Prostate Cancer Growth
Investigators sought to identify Vav3 binding partners in an effort to understand the molecular mechanisms underlying Vav3 enhancement of androgen receptor activity and to identify new therapeutic targets. The cell division cycle 37 homolog (Cdc37), a protein kinase-specific co-chaperone for Hsp90, was identified as a Vav3 interacting protein by yeast two hybrid screening. [J Biol Chem] Abstract

The Wilms’ Tumor Gene (WT1) Regulates E-Cadherin Expression and Migration of Prostate Cancer Cells
To better understand the effect of WT1 on E-cadherin expression and migration of prostate cancer (PCa) cells, scientists quantified WT1 and E-cadherin mRNA levels in normal prostate epithelial and PCa cell lines with varying migratory potential. [Mol Cancer] Abstract | Full Article

Anterior Gradient 2 and 3: Two Prototype Androgen Responsive Genes Transcriptionally Upregulated by Androgens and by Estrogens in Prostate Cancer Cells
The authors analyzed the effect of androgens and estrogens on the expression of AGR2 and AGR3, two highly related genes encoding secretory proteins that are expressed in prostate cancer and one of which has been associated with tumor metastasis. [FEBS J] Abstract

Platelet-Derived Growth Factor-BB Accelerates Prostate Cancer Growth by Promoting the Proliferation of Mesenchymal Stem Cells
Investigators report that mesenchymal stem cells promoted prostate cancer (PCa) tumor growth in vivo and cell proliferation in vitro by using PCa cell strain RM-1. [J Cell Biochem] Abstract
 
Combining T-Cell Immunotherapy and Anti-Androgen Therapy for Prostate Cancer
Scientists demonstrated that T cells can be genetically engineered to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen Muc1. CAR-Muc1 T cells were able to selectively kill Muc1-expressing human prostate cancer cells.[Prostate Cancer Prostatic Dis] Abstract

Apoptosis Induction of Human Prostate Carcinoma Cells by Cordycepin through Reactive Oxygen Species-Mediated Mitochondrial Death Pathway
Scientists investigated the apoptotic effects of cordycepin in human prostate carcinoma cells. They found that treatment with cordycepin significantly inhibited cell growth by inducing apoptosis in PC-3 cells. [Int J Oncol] Abstract

CLINICAL RESEARCH

2-Weekly versus 3-Weekly Docetaxel to Treat Castration-Resistant Advanced Prostate Cancer: A Randomized, Phase III Trial
The authors hypothesized that 2-weekly administration of docetaxel would be better tolerated than 3-weekly docetaxel in patients with castration-resistant advanced prostate cancer, and did a prospective, multicenter, randomized, Phase III study to compare efficacy and safety. [Lancet Oncol] Abstract

Prostate Cancer Diagnosis among Men with Isolated High-Grade Intraepithelial Neoplasia Enrolled onto a 3-Year Prospective Phase III Clinical Trial of Oral Toremifene
Researchers evaluated the efficacy of toremifene citrate in prostate cancer prevention among men with isolated high-grade prostatic intraepithelial neoplasia on biopsy. [J Clin Oncol] Abstract

Enzalutamide: A Novel Anti-Androgen for Patients with Castrate Resistant Prostate Cancer
In a Phase III randomized study comparing Enzalutamide to placebo in men with progressive castration resistant prostate cancer who were previously treated with docetaxel, Enzalutamide showed an improvement in overall survival. [Clin Cancer Res] Abstract

Aragon Wins Key Legal Ruling Against Medivation
Aragon Pharmaceuticals Inc. announced that the Superior Court of California, County of San Francisco, granted summary adjudication in favor of Aragon on its Complaint in Intervention against Medivation, holding that Aragon has “exclusive rights to the A-Series compounds,” including ARN-509. ARN-509, a novel second-generation anti-androgen is currently in a Phase II clinical trial for advanced castration-resistant prostate cancer. [Aragon Pharmaceuticals, Inc.] Press Release

Sanford-Burnham Medical Research Institute and Intrexon Corporation Establish Collaboration to Accelerate Stem Cell Research
Sanford-Burnham Medical Research Institute and Intrexon Corporation announced a new collaboration to accelerate stem cell research. [Intrexon Corporation] Press Release

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

NEW The 3rd International Congress on Controversies in Cryopreservation of Stem Cells, Reproductive Cells, Tissue and Organs (CRYO)
March 21-22, 2013
Berlin, Germany

Visit our events page to see a complete list of events in the prostate cell community.

Scientist or Engineer – hPSC Bioengineer (STEMCELL Technologies, Inc.)

PhD Studentship – Investigation into Chemokine Receptor Induced Cell Migration (University of East Anglia)

Postdoctoral Position – Convergence of the ZMIZ1 and NOTCH1 Pathways at C-MYC in Acute T Lymphoblastic Leukemias (University of Michigan – Ann Arbor)

Postdoctoral Position – Androgen Receptor Genomics (The Netherlands Cancer Institute)

Associate Professor – Urologic Cancers (Oregon Health & Science University [OHSU])

Assistant, Associate or Full Professor – Cancer Early Detection (Stanford University School of Medicine)

Postdoctoral Position – Cellular and Molecular Studies of Prostate Cancer (Columbia University Medical Center)

Recruit Top Talent : Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.